Invasive Fungal Infection Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Disease Type (Candidaemi Caa and Invasive Candiasis, Intra-abdominal Candiasis, Cryptococcal Meningitis, Esophageal Candidiasis, Histoplasmosis Acute Pulmonary, Others), by Drug Type (Polyenes, Amphotericin B Deoxycholate, Lipid Formulation Amphotericin B, Others), by region, and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 7.83 Billion
CAGR (2026-2031)	3.76%
Fastest Growing Segment	Candidaemi Caa and Invasive Candiasis
Largest Market	North America
Market Size (2031)	USD 9.77 Billion

Market Overview

The Global Invasive Fungal Infection Market will grow from USD 7.83 Billion in 2025 to USD 9.77 Billion by 2031 at a 3.76% CAGR. The Global Invasive Fungal Infection Market comprises systemic antifungal pharmacotherapies and diagnostic solutions designed to manage severe mycoses invading internal body tissues. Primary growth drivers include the rising prevalence of immunocompromised individuals, such as oncology patients and organ transplant recipients, coupled with the escalation of hospital-acquired infections. According to the Global Action For Fungal Infections, in 2024, invasive fungal pathogens were estimated to contribute to approximately 3.8 million deaths annually worldwide, underscoring the urgent clinical demand for effective therapeutic interventions.

A significant impediment to market expansion is the increasing phenomenon of antifungal resistance, which renders established therapies ineffective and necessitates high-risk capital investment for novel drug development. This challenge is compounded by the high toxicity profiles associated with potent antifungal agents like amphotericin B, which can limit clinical application and adoption rates in vulnerable patient demographics.

Key Market Drivers

The rising prevalence of immunocompromised patient populations serves as a critical catalyst for the Global Invasive Fungal Infection Market. Individuals undergoing aggressive chemotherapy, recipients of solid organ transplants, and those living with advanced HIV/AIDS present with severely weakened immune defenses, rendering them acutely susceptible to life-threatening opportunistic pathogens such as Cryptococcus and Aspergillus. This expanding vulnerable demographic necessitates robust prophylactic and therapeutic antifungal regimens, directly fueling product uptake. According to the Centers for Disease Control and Prevention, April 2024, in the 'Cryptococcosis Facts and Stats' update, cryptococcal meningitis alone accounts for an estimated 112,000 deaths annually among people with HIV/AIDS worldwide, highlighting the critical need for effective intervention in these high-risk groups.

Concurrently, growing government initiatives and funding for infectious disease control are accelerating market innovation, specifically to counter the escalation of multi-drug resistant fungal strains. Recognizing the public health threat, federal agencies are increasingly deploying capital to de-risk the development of novel therapeutics. For example, according to the Center for Infectious Disease Research and Policy, September 2024, in the 'BARDA funds 2 antifungal drug candidates' article, the Biomedical Advanced Research and Development Authority awarded $29 million to Basilea Pharmaceutica to advance novel antifungals. These strategic investments support a commercially viable sector; according to Basilea Pharmaceutica, in September 2024, global in-market sales of the antifungal Cresemba reached $489 million over the prior twelve months, reflecting the substantial economic scale of effective fungal management.

Download Free Sample Report

Key Market Challenges

The increasing phenomenon of antifungal resistance significantly hampers the Global Invasive Fungal Infection Market by eroding the commercial viability of existing pharmacotherapies and escalating the cost of innovation. As fungal pathogens develop tolerance to standard drug classes such as azoles and echinocandins, pharmaceutical companies are compelled to invest heavily in high-risk research and development to identify novel therapeutic targets. This necessity for continuous innovation creates a steep barrier to entry and compresses the profitability window for new agents, as antimicrobial stewardship programs often restrict novel drugs to last-line therapy, thereby limiting their immediate volume of sales and revenue generation.

This challenge is directly magnified by the sheer scale of the patient population requiring complex, resistance-conscious management. According to the Global Action Fund for Fungal Infections, in 2024, the global incidence of invasive fungal infections was estimated to reach 6.5 million cases annually. The widening prevalence of resistant strains within this massive demographic complicates clinical decision-making and increases the financial strain on healthcare providers, creating market friction that slows the adoption of premium-priced, next-generation antifungal agents despite the clear clinical urgency.

Key Market Trends

The emergence of first-in-class antifungal drug classes is reshaping the therapeutic landscape as developers introduce novel mechanisms of action to combat resistant pathogens. Unlike traditional azoles or echinocandins, these next-generation agents, such as orotomides, target previously unexploited fungal pathways to treat invasive molds like Aspergillus without cross-resistance. This innovation is attracting substantial late-stage investment to bring these differentiated assets to market. According to F2G, September 2024, in the 'F2G Announces $100 Million Financing' press release, the biotech secured $100 million to finalize the development and regulatory resubmission of olorofim, the premier candidate of the new orotomide class, demonstrating the high commercial value placed on overcoming existing therapeutic limitations.

Concurrently, the widespread adoption of rapid molecular diagnostic technologies is replacing time-consuming culture methods with culture-independent solutions capable of detecting fungal DNA in hours. Healthcare facilities are increasingly integrating platforms that utilize magnetic resonance and multiplex polymerase chain reaction to accelerate time-to-result, enabling clinicians to initiate targeted therapy much earlier in the infection course. This shift is driving significant commercial uptake of direct-from-blood testing systems. According to T2 Biosystems, November 2024, in the 'T2 Biosystems Announces Third Quarter 2024 Financial Results', the company achieved a 34% year-over-year increase in sepsis test panel revenue, reflecting the critical market shift toward speed and accuracy in fungal detection.

Segmental Insights

The Candidemia and Invasive Candidiasis segment is currently the fastest-growing category within the Global Invasive Fungal Infection Market, primarily driven by the increasing incidence of healthcare-associated bloodstream infections. This surge is closely linked to the expanding population of immunocompromised patients, such as those undergoing chemotherapy or organ transplantation, who are highly susceptible to systemic fungal pathogens. Furthermore, the emergence of multidrug-resistant strains has intensified the urgent demand for effective therapeutics. Enhanced surveillance and awareness initiatives by organizations like the Centers for Disease Control and Prevention (CDC) have further highlighted the critical need for advanced treatments, sustaining the segment's rapid expansion.

Regional Insights

North America commands the leading share of the Global Invasive Fungal Infection Market, driven by a highly developed healthcare system and the widespread adoption of advanced antifungal therapies. The region faces a growing burden of infections among immunocompromised patients, sustaining the demand for effective clinical interventions. This dominance is reinforced by supportive regulatory frameworks; specifically, the U.S. Food and Drug Administration (FDA) accelerates the approval of novel drugs to counter resistance. Additionally, the Centers for Disease Control and Prevention (CDC) actively improves diagnostic standards through robust surveillance programs, ensuring timely patient management across the region.

Recent Developments

• In July 2025, Basilea Pharmaceutica Ltd. received $39 million in funding from the Biomedical Advanced Research and Development Authority (BARDA) to accelerate its antifungal development program. This financing was part of a broader long-term agreement aimed at supporting novel, first-in-class antimicrobials. The company indicated that the funds would support an ongoing Phase 3 clinical study of fosmanogepix for invasive yeast infections and the initiation of a late-stage trial for invasive mold infections. Furthermore, the capital was allocated to prepare for a Phase 2 study of BAL2062, another antifungal asset in the company's portfolio targeting difficult-to-treat molds such as Aspergillus.
• In May 2025, Scynexis, Inc. resumed patient dosing in its global Phase 3 MARIO study evaluating ibrexafungerp for the treatment of invasive candidiasis. This operational restart followed the lifting of a clinical hold by the U.S. Food and Drug Administration (FDA), which had been imposed due to earlier manufacturing concerns. The company utilized newly manufactured clinical supplies to proceed with the trial, which investigates the oral antifungal as a step-down therapy following initial intravenous treatment. Resuming this pivotal study triggered a milestone payment from the company's partner, supporting the continued advancement of this novel agent for severe hospital-based infections.
• In September 2024, F2G Ltd. secured $100 million in a new financing round led by the AMR Action Fund to advance the late-stage development and commercialization of its novel antifungal candidate, olorofim. The company announced that the proceeds would be directed toward completing ongoing clinical trials and preparing for regulatory submissions in the United States. Olorofim represents the first member of a new class of antifungal agents known as orotomides and is being developed to treat invasive aspergillosis and other rare fungal infections. This investment facilitates delivering a differentiated therapy to patients with severe infections who have exhausted other treatment options.
• In January 2024, Cidara Therapeutics announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom approved Rezzayo (rezafungin acetate) for the treatment of invasive candidiasis in adults. This regulatory authorization expanded the range of therapeutic options available for patients suffering from these life-threatening systemic fungal infections. Rezzayo is described as a novel, once-weekly echinocandin antifungal specifically designed to improve upon the pharmacokinetics of existing standards of care. The company emphasized that this approval marked a critical advancement in addressing the significant unmet medical needs of critically ill patients in hospital settings who often have limited effective alternatives.

Key Market Players

• Cidara Therapeutics, Inc.
• Basilea Pharmaceutica AG Allschwil
• Pfizer Inc.
• GlaxoSmith Kline
• Bayer AG
• Abbott Laboratories Ltd.
• Merck & Co, Inc.
• Astellas Pharma Inc.
• Scynexis Inc.
• Matinas BioPharma Holdings, Inc

By Disease Type	By Region
Candidaemi Caa and Invasive Candiasis Intra-abdominal Candiasis Cryptococcal Meningitis Esophageal Candidiasis Histoplasmosis Acute Pulmonary Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Invasive Fungal Infection Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Invasive Fungal Infection Market, By Disease Type:

• Candidaemi Caa and Invasive Candiasis
• Intra-abdominal Candiasis
• Cryptococcal Meningitis
• Esophageal Candidiasis
• Histoplasmosis Acute Pulmonary
• Others

• Invasive Fungal Infection Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE